Keros Therapeutics has dosed the first patient in a Phase 2 trial of Rinvatercept targeting Duchenne muscular dystrophy. As a clinical-stage biopharmaceutical company with no current drug products on the market, this trial initiation is a significant milestone for its neuromuscular development strategy.